Haleon/$HLN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Haleon
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Ticker
$HLN
Sector
Primary listing
NYSE
Employees
24,561
Headquarters
Website
Haleon Metrics
BasicAdvanced
$42B
42.69
$0.22
0.24
$0.18
1.22%
Price and volume
Market cap
$42B
Beta
0.24
52-week high
$11.42
52-week low
$8.71
Average daily volume
9.4M
Dividend rate
$0.18
Financial strength
Current ratio
0.87
Quick ratio
0.605
Long term debt to equity
48
Total debt to equity
53.413
Dividend payout ratio (TTM)
39.22%
Interest coverage (TTM)
6.38%
Profitability
EBITDA (TTM)
3,429.976
Gross margin (TTM)
63.56%
Net profit margin (TTM)
13.81%
Operating margin (TTM)
21.84%
Effective tax rate (TTM)
22.88%
Revenue per employee (TTM)
$587,770
Management effectiveness
Return on assets (TTM)
4.61%
Return on equity (TTM)
9.38%
Valuation
Price to earnings (TTM)
42.695
Price to revenue (TTM)
5.86
Price to book
2.02
Price to tangible book (TTM)
-3.42
Price to free cash flow (TTM)
30.101
Free cash flow yield (TTM)
3.32%
Free cash flow per share (TTM)
0.309
Dividend yield (TTM)
1.95%
Forward dividend yield
1.22%
Growth
Revenue change (TTM)
-2.12%
Earnings per share change (TTM)
41.64%
3-year revenue growth (CAGR)
2.75%
3-year earnings per share growth (CAGR)
2.88%
What the Analysts think about Haleon
Analyst ratings (Buy, Hold, Sell) for Haleon stock.
Bulls say / Bears say
Haleon’s Q3 2025 organic revenue growth of 3.4% exceeded analyst expectations of 3.3%, driven by a 6.9% rise in its high-margin Oral Health segment led by Sensodyne. This allowed the company to maintain its full-year 2025 organic growth forecast of around 3.5% (Reuters).
In Q1 2025, Haleon reported 3.5% organic revenue growth, topping the analyst consensus of 3.2%, backed by strong demand for Sensodyne and Parodontax Oral Health products. This outperformance offset weaker sales in Respiratory and Digestive segments and reinforced the company’s full-year guidance (Reuters).
At its Capital Markets Day in May 2025, Haleon projected high single-digit percentage growth in adjusted operating profit starting in 2026. The forecast is supported by £800 million in productivity savings and a 30% annual reduction in working capital, indicating robust margin expansion and improved cash flow prospects (Reuters).
In July 2025, Haleon cut its annual organic revenue growth guidance to about 3.5% from 4–6%, due to weaker-than-expected demand in North America. This led to a 4.3% decline in its share price on the day of the announcement (Reuters).
North American organic sales in Q3 2025 grew only 0.4%, reflecting continued consumer spending pressure and retailer destocking in its largest market (Reuters).
In March 2025, Pfizer sold its entire stake in Haleon—representing 7.3% of issued share capital—removing a long-term strategic investor and potentially reducing shareholder support and stability for the stock (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
Haleon Financial Performance
Revenues and expenses
Haleon Earnings Performance
Company profitability
Haleon News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Haleon stock?
Haleon (HLN) has a market cap of $42B as of November 06, 2025.
What is the P/E ratio for Haleon stock?
The price to earnings (P/E) ratio for Haleon (HLN) stock is 42.69 as of November 06, 2025.
Does Haleon stock pay dividends?
Yes, the Haleon (HLN) stock pays dividends to shareholders. As of November 06, 2025, the dividend rate is $0.18137 and the yield is 1.22%. Haleon has a payout ratio of 39.22% on a trailing twelve-month basis.
When is the next Haleon dividend payment date?
The next Haleon (HLN) dividend payment date is unconfirmed.
What is the beta indicator for Haleon?
Haleon (HLN) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.